OncoMatch/Clinical Trials/NCT06029309
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Is NCT06029309 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Zanubrutinib and Tafasitamab for mantle cell lymphoma.
Treatment: Zanubrutinib · Tafasitamab — The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: investigational agent
Patients receiving any other investigational agents
Cannot have received: allogenic hematopoietic stem cell transplantation
History of allogenic hematopoietic stem cell transplantation prior to enrollment
Cannot have received: corticosteroids
Exception: ≤ prednisone 10 mg/day or its equivalent with antineoplastic intent within 7 days of the start of study drug
Prior corticosteroids in excess of prednisone 10 mg/day or its equivalent with antineoplastic intent within 7 days of the start of study drug
Cannot have received: chemotherapy
Exception: within 3 weeks of the start of study drug
Prior chemotherapy, targeted therapy, or radiation therapy within 3 weeks
Cannot have received: targeted therapy
Exception: within 3 weeks of the start of study drug
Prior chemotherapy, targeted therapy, or radiation therapy within 3 weeks
Cannot have received: radiation therapy
Exception: within 3 weeks of the start of study drug
Prior chemotherapy, targeted therapy, or radiation therapy within 3 weeks
Cannot have received: antineoplastic therapy with Chinese herbal medication
Exception: within 4 weeks of the start of study drug
antineoplastic therapy with Chinese herbal medication or antibody-based therapies within 4 weeks of the start of study drug
Cannot have received: antibody-based therapies
Exception: within 4 weeks of the start of study drug
antineoplastic therapy with Chinese herbal medication or antibody-based therapies within 4 weeks of the start of study drug
Cannot have received: live vaccine
Exception: within 28 days prior to start of study treatment
Administration of live vaccine within 28 days prior to start of study treatment
Lab requirements
Blood counts
Absolute neutrophil count >1,000/mm3 independent of growth factor support within 7 days of study entry (>700/mm3 if lymphoma involvement of the bone marrow or spleen); Platelets >70,000/mm3 independent of transfusion support within 7 days of study entry (>50,000/mm3 if lymphoma involvement of the bone marrow or spleen); Hemoglobin >9 g/dL or >8 g/dL in case of bone marrow involvement by lymphoma independent of transfusion support within 7 days of study entry
Kidney function
Creatinine within normal institutional limits, or creatinine clearance ≥ 40 mL/min (creatinine clearance ≥ 30 mL/min if due to lymphoma)
Liver function
Total bilirubin < 1.5 x within normal institutional limits (unless known history of Gilbert's disease or up to 3 x ULN if due to lymphoma involvement of liver); GGT/AST/ALT ≤ 2.5 x institutional upper limit of normal
Cardiac function
QTcF ≤ 450 msec; no significant ECG abnormalities including second-degree atrioventricular block Type II, or third-degree atrioventricular block
Patients must have normal organ and marrow function as defined below: ... QT interval corrected with Fridericia's formula (QTcF) > 450 msec or other significant ECG abnormalities including second-degree atrioventricular block Type II, or third-degree atrioventricular block
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify